Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth (Status and Outlook) 2025-2031

January 2025 | 91 pages | ID: G97537740ECEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is predicted to grow from US$ 2612 million in 2025 to US$ 22970 million in 2031; it is expected to grow at a CAGR of 43.7% from 2025 to 2031.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

LPI (LP Information)' newest research report, the “Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy (DMD) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy (DMD) Therapeutics sales for 2025 through 2031. With Duchenne Muscular Dystrophy (DMD) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy (DMD) Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy (DMD) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy (DMD) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy (DMD) Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy (DMD) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy (DMD) Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy (DMD) Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Exondys
• Emflaza
• Translarna

Segmentation by Application:

• Hospitals
• Clinics
• Home Care

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Sarepta Therapeutics
• PTC Therapeutics
• Pfizer
• Bristol-Myers Squibb
• Italfarmaco
• Santhera Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
  2.1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Duchenne Muscular Dystrophy (DMD) Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type
  2.2.1 Exondys
  2.2.2 Emflaza
  2.2.3 Translarna
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2020-2025)
2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
  2.4.1 Hospitals
  2.4.2 Clinics
  2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  2.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2020-2025)

3 DUCHENNE MUSCULAR DYSTROPHY (DMD) THERAPEUTICS MARKET SIZE BY PLAYER

3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Player
  3.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Player (2020-2025)
  3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Player (2020-2025)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 DUCHENNE MUSCULAR DYSTROPHY (DMD) THERAPEUTICS BY REGION

4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2020-2025)
4.4 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2020-2025)
4.5 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2020-2025)
4.6 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
5.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025)
5.3 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
6.2 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025)
6.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025)
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025)
8.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY (DMD) THERAPEUTICS MARKET FORECAST

10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2026-2031)
  10.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2026-2031)
  10.1.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.1.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.1.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.1.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.2 Americas Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Country (2026-2031)
  10.2.1 United States Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.2.2 Canada Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.2.3 Mexico Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.2.4 Brazil Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.3 APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2026-2031)
  10.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast
  10.3.2 Japan Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.3.3 Korea Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.3.4 Southeast Asia Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.3.5 India Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.3.6 Australia Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Country (2026-2031)
  10.4.1 Germany Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.4.2 France Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.4.3 UK Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.4.4 Italy Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.4.5 Russia Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Region (2026-2031)
  10.5.1 Egypt Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.5.2 South Africa Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.5.3 Israel Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
  10.5.4 Turkey Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast
10.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Type (2026-2031)
10.7 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Duchenne Muscular Dystrophy (DMD) Therapeutics Forecast

11 KEY PLAYERS ANALYSIS

11.1 Sarepta Therapeutics
  11.1.1 Sarepta Therapeutics Company Information
  11.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Sarepta Therapeutics Main Business Overview
  11.1.5 Sarepta Therapeutics Latest Developments
11.2 PTC Therapeutics
  11.2.1 PTC Therapeutics Company Information
  11.2.2 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 PTC Therapeutics Main Business Overview
  11.2.5 PTC Therapeutics Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments
11.4 Bristol-Myers Squibb
  11.4.1 Bristol-Myers Squibb Company Information
  11.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Bristol-Myers Squibb Main Business Overview
  11.4.5 Bristol-Myers Squibb Latest Developments
11.5 Italfarmaco
  11.5.1 Italfarmaco Company Information
  11.5.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Italfarmaco Main Business Overview
  11.5.5 Italfarmaco Latest Developments
11.6 Santhera Pharmaceuticals
  11.6.1 Santhera Pharmaceuticals Company Information
  11.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
  11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Santhera Pharmaceuticals Main Business Overview
  11.6.5 Santhera Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Duchenne Muscular Dystrophy (DMD)Therapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Exondys
Table 4. Major Players of Emflaza
Table 5. Major Players ofTranslarna
Table 6. Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size CAGR byType (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size byType (2020-2025) & ($ millions)
Table 8. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType (2020-2025)
Table 9. Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application (2020-2025)
Table 12. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue Market Share by Player (2020-2025)
Table 14. Duchenne Muscular Dystrophy (DMD)Therapeutics Key Players Head office and Products Offered
Table 15. Duchenne Muscular Dystrophy (DMD)Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Region (2020-2025)
Table 20. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Country (2020-2025)
Table 24. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size byType (2020-2025) & ($ millions)
Table 25. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType (2020-2025)
Table 26. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application (2020-2025)
Table 28. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Region (2020-2025)
Table 30. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size byType (2020-2025) & ($ millions)
Table 31. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Country (2020-2025)
Table 34. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size byType (2020-2025) & ($ millions)
Table 35. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size byType (2020-2025) & ($ millions)
Table 38. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy (DMD)Therapeutics
Table 40. Key Market Challenges & Risks of Duchenne Muscular Dystrophy (DMD)Therapeutics
Table 41. Key IndustryTrends of Duchenne Muscular Dystrophy (DMD)Therapeutics
Table 42. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market SizeForecast by Region (2026-2031) & ($ millions)
Table 43. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market ShareForecast by Region (2026-2031)
Table 44. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market SizeForecast byType (2026-2031) & ($ millions)
Table 45. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market SizeForecast by Application (2026-2031) & ($ millions)
Table 46. SareptaTherapeutics Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 47. SareptaTherapeutics Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 48. SareptaTherapeutics Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. SareptaTherapeutics Main Business
Table 50. SareptaTherapeutics Latest Developments
Table 51. PTCTherapeutics Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 52. PTCTherapeutics Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 53. PTCTherapeutics Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. PTCTherapeutics Main Business
Table 55. PTCTherapeutics Latest Developments
Table 56. Pfizer Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 57. Pfizer Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 58. Pfizer Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Pfizer Main Business
Table 60. Pfizer Latest Developments
Table 61. Bristol-Myers Squibb Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 62. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 63. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Bristol-Myers Squibb Main Business
Table 65. Bristol-Myers Squibb Latest Developments
Table 66. Italfarmaco Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 67. Italfarmaco Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 68. Italfarmaco Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Italfarmaco Main Business
Table 70. Italfarmaco Latest Developments
Table 71. Santhera Pharmaceuticals Details, CompanyType, Duchenne Muscular Dystrophy (DMD)Therapeutics Area Served and Its Competitors
Table 72. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD)Therapeutics Product Offered
Table 73. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Santhera Pharmaceuticals Main Business
Table 75. Santhera Pharmaceuticals Latest Developments



LIST OFFIGURES

Figure 1. Duchenne Muscular Dystrophy (DMD)Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Duchenne Muscular Dystrophy (DMD)Therapeutics Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Duchenne Muscular Dystrophy (DMD)Therapeutics Sales Market Share by Country/Region (2024)
Figure 8. Duchenne Muscular Dystrophy (DMD)Therapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType in 2024
Figure 10. Duchenne Muscular Dystrophy (DMD)Therapeutics in Hospitals
Figure 11. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market: Hospitals (2020-2025) & ($ millions)
Figure 12. Duchenne Muscular Dystrophy (DMD)Therapeutics in Clinics
Figure 13. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market: Clinics (2020-2025) & ($ millions)
Figure 14. Duchenne Muscular Dystrophy (DMD)Therapeutics in Home Care
Figure 15. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market: Home Care (2020-2025) & ($ millions)
Figure 16. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application in 2024
Figure 17. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Revenue Market Share by Player in 2024
Figure 18. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Region (2020-2025)
Figure 19. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2020-2025 ($ millions)
Figure 20. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2020-2025 ($ millions)
Figure 21. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2020-2025 ($ millions)
Figure 23. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Value Market Share by Country in 2024
Figure 24. United States Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Region in 2024
Figure 29. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType (2020-2025)
Figure 30. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application (2020-2025)
Figure 31. China Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 35. India Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Country in 2024
Figure 38. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType (2020-2025)
Figure 39. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application (2020-2025)
Figure 40. Germany Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 41.France Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share byType (2020-2025)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 51.Turkey Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 54. APAC Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 55. Europe Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 57. United States Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 58. Canada Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 59. Mexico Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 60. Brazil Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 61. China Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 62. Japan Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 63. Korea Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 65. India Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 66. Australia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 67. Germany Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 68.France Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 69. UK Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 70. Italy Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 71. Russia Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 72. Egypt Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 73. South Africa Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 74. Israel Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 75.Turkey Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)
Figure 76. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market ShareForecast byType (2026-2031)
Figure 77. Global Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size Market ShareForecast by Application (2026-2031)
Figure 78. GCC Countries Duchenne Muscular Dystrophy (DMD)Therapeutics Market Size 2026-2031 ($ millions)